Clinical trial
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With…
NCT00021060 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00021060 |
|---|---|
| Title | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer |
| Official title | Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | paclitaxel, carboplatin, bevacizumab, laboratory biomarker analysis |
| Enrollment | 842 |
| Start date | Aug 1, 2002 |
| Primary completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: